BioCentury
ARTICLE | Company News

Teva, Mylan autoimmune news

October 4, 2010 7:00 AM UTC

Teva filed a complaint in the U.S. District Court for the Southern District of New York adding four additional patents to its 2009 suit against Mylan related to Teva's multiple sclerosis (MS) drug Copaxone glatiramer acetate injection. A trial date has not yet been scheduled. Last year, Teva sued Mylan and Natco Pharma Ltd. (BSE:524816, Hyderabad, India) in the same court, alleging that Mylan's September 2009 ANDA for generic Copaxone infringes seven U.S. patents, which expire in 2014. Mylan has a deal with Natco to manufacture generic Copaxone. ...